Clinical trials: Genome
Solid Tumour, Haematological Malignancy
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer.
- Conditions
- Solid Tumour, Haematological Malignancy, Malignant Neoplasm, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT06988475)
- Testing
- Capmatinib
- Where
- 17 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Cancer
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
Foretinib (GSK1363089) is an investigational, oral, multikinase inhibitor involved in invasion, migration, and angiogenesis. This is a phase II, open label, uncontrolled, parallel, multi-cohort, multicenter 2-stage study to…
- Trial name
- NCT02034097
- Testing
- Foretinib, Erlotinib
- Sponsor
- GlaxoSmithKline
Triple Negative Breast Cancer
Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer
The primary objective is to describe and discover new insights into the glucose, amino acid, and lipid metabolic dependencies of TNBC via nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo [1,2-13C] glucose-labeled…
- Trial name
- NCT03457779
- Testing
- Glucose
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Baylor Research Institute
Relapsed Refractory Multiple Myeloma
Myeloma-Developing Regimens Using Genomics (MyDRUG)
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer.
- Trial name
- MyDRUG (NCT03732703)
- Testing
- Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib, dexamethasone, ixazomib, pomalidomide, Cobimetinib, dexamethasone, ixazomib, pomalidomide
- Where
- 16 sites in United States
- Volunteers
- 103 people
- Sponsor
- Multiple Myeloma Research Consortium
Breast Cancer
Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast…
- Trial name
- NCT04517266
- Testing
- omit of IMI group, IMI group
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Ruijin Hospital
Cirrhosis, MASLD
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD
The Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a leading cause of chronic liver disease globally, with a prevalence exceeding 30% in the population.
- Trial name
- NCT07249112
- Testing
- genetic and somatic variants involved in its progression toward advanced fibrosis and hepatocellular carcinoma
- Where
- Italy
- Volunteers
- 2,880 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Pancreatic Cancer, Liver Metastases
A Study of Pancreatic Cancer in Xenografts From Liver Metastases
This is a feasibility study to perform image-guided liver biopsies in 25 patients who have pancreatic cancer with liver metastasis (cancer in the pancreas that has spread to the liver).
- Conditions
- Pancreatic Cancer, Liver Metastases, Tumor Tissue Biopsy, Blood Samples
- Trial name
- NCT01774643
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- University Health Network, Toronto
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a…
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma
- Trial name
- NCT04284774
- Testing
- Tipifarnib
- Where
- 172 sites in United States, Puerto Rico
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Brain Neoplasms
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme.
- Trial name
- NCT01954576
- Testing
- NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Florida
Chronic Lymphocytic Leukemia
Genomic Analysis of Patients With Chronic Lymphocytic Leukemia
This study aims to characterize clonal evolution in chronic lymphocytic leukemia (CLL) using different approaches and to identify a possible association with disease progression, i.e. therapy initiation. 1.
- Trial name
- NCT01346020
- Where
- Belgium
- Volunteers
- 53 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Chronic Kidney Disease, Pediatric
The Cardiovascular Comorbidity in Children With Chronic Kidney Disease Study
Children and adolescents with chronic kidney disease (CKD) are at high risk for cardiovascular (CV) morbidity and mortality. Recent studies suggest that pediatric patients with even moderately impaired kidney function may be…
- Conditions
- Chronic Kidney Disease, Pediatric, Cardiovascular Disease
- Trial name
- 4C (NCT01046448)
- Where
- 50 sites in Austria, Belgium and 13 more
- Volunteers
- 650 people
- Sponsor
- Heidelberg University
Neoplastic Syndromes, Hereditary
Applying Population Management Best Practices to Preventative Genomic Medicine Trial
Preventive genomic medicine, particularly identification of individuals with inherited cancer risk, can improve longevity and quality of life, yet adherence to risk management following cancer genomic testing is poor.
- Trial name
- CARE-HCS (NCT07053813)
- Testing
- Web resources, Personalized outreach
- Where
- 2 sites in United States
- Volunteers
- 900 people
- Sponsor
- University of Washington
MDS (Myelodysplastic Syndrome)
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care
BACKGROUND Myelodysplastic syndromes (MDS) typically occur in elderly people and with time, a portion of the patients evolve into acute myeloid leukemia (AML). Therefore a risk-adapted treatment strategy is mandatory.
- Trial name
- FISiM-NGS-MDS (NCT04212390)
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
Acute Kidney Injury, Renal Insufficiency, Chronic
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
In the last decade, transcatheter aortic valve replacement (TAVR) has become an increasingly utilized alternative procedure for replacing a stenotic aortic valve.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Chronic, Heart Failure, Myocardial Infarction
- Trial name
- NCT02791880
- Testing
- Transcatheter Aortic Valve Replacement
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Texas Southwestern Medical Center
Thyroid Nodule, Thyroid Cancer
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
The purpose of this study is to evaluate the accuracy of Thyroscan in the differential diagnosis of benign and malignant thyroid nodules with suspecious ultrasound features
- Trial name
- NCT05025046
- Testing
- Thyroscan
- Where
- 4 sites in China
- Volunteers
- 250 people
- Sponsor
- Rigen Biotech
Whole Genome Sequencing, Genetic Disease
N-Care Project: Enhancing Asian-Pacific Collaboration
Through Asian-Pacific multinational collaboration, we aim to utilize third-generation genome sequencing to rapidly diagnose genetic diseases in critically ill infants and young children, achieving the goal of early diagnosis for…
- Conditions
- Whole Genome Sequencing, Genetic Disease, Critical Care, Intensive Care, Nanopore Sequencing
- Trial name
- N-Care project (NCT06821386)
- Testing
- Genetic study with nanopore sequencing
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
Cancer of Unknown Primary, Neoplasm, Unknown Primary
Enabling Genomic Testing in Cancer of Unknown Primary
Cancer of Unknown Primary (CUP) is where cancer cells are found in the body but the place the cancer began is not known. It is the 6th leading cause of cancer death in the UK and the prognosis is poor with a median survival of…
- Trial name
- EGGCUP (NCT06695494)
- Testing
- Gene panel array, Blood Sample Collection
- Where
- 6 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Christie NHS Foundation Trust
Leukemia
Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy
RATIONALE: Studying samples of DNA in the laboratory from patients who received fludarabine-based treatment may help doctors learn more about the effects of fludarabine on cells.
- Trial name
- NCT01145469
- Testing
- DNA analysis, gene expression analysis, polymorphism analysis
- Volunteers
- 225 people
- Sponsor
- Eastern Cooperative Oncology Group
Melanoma, Pancreas Cancer
Integration of Whole-Genome Sequencing PrOfiles and ImmuNe StATus in Cancer
The goal of this investigator-initiated tumour profiling study is to analyse the relation between genomic alterations and the tumour immune contexture in patients with advanced melanoma and pancreatic cancer with resistance to…
- Trial name
- SONATA (NCT07796594)
- Testing
- Biopsy
- Where
- Netherlands
- Volunteers
- 180 people
- Sponsor
- Amsterdam UMC, location VUmc
Prostate Cancer
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response.
- Trial name
- GUNS (NCT04812366)
- Testing
- Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab
- Where
- 9 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of British Columbia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.